Roth Capital Comments on Aptose Biosciences Inc.’s FY2016 Earnings (APTO)
Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) – Equities research analysts at Roth Capital raised their FY2016 earnings per share estimates for shares of Aptose Biosciences in a research report issued on Tuesday. Roth Capital analyst J. Pantginis now anticipates that the firm will earn ($1.11) per share for the year, up from their previous estimate of ($1.39). Roth Capital currently has a “Buy” rating and a $8.00 target price on the stock. Roth Capital also issued estimates for Aptose Biosciences’ Q4 2016 earnings at ($0.24) EPS and FY2017 earnings at ($0.85) EPS.
A number of other analysts also recently issued reports on APTO. Zacks Investment Research raised shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research report on Thursday. RBC Capital Markets restated an “outperform” rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Royal Bank Of Canada decreased their price target on Aptose Biosciences from $18.00 to $12.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Canaccord Genuity restated a “buy” rating and issued a $7.00 price target on shares of Aptose Biosciences in a report on Saturday, October 15th. Six investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $9.50.
Shares of Aptose Biosciences (NASDAQ:APTO) opened at 0.92 on Thursday. Aptose Biosciences has a 12-month low of $0.83 and a 12-month high of $4.33. The firm’s market cap is $11.86 million. The firm’s 50-day moving average is $1.65 and its 200-day moving average is $2.24.
An institutional investor recently bought a new position in Aptose Biosciences stock. Bank of Montreal Can bought a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned approximately 0.43% of Aptose Biosciences at the end of the most recent quarter. Institutional investors own 19.19% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.